Publication
An Antisense Oligonucletide based therapy for a rare disease: in vitro and in vivo studies
| dc.contributor.author | Gonçalves, M. | |
| dc.contributor.author | Matos, L. | |
| dc.contributor.author | Santos, J.I. | |
| dc.contributor.author | Coutinho, M.F. | |
| dc.contributor.author | Prata, M.J. | |
| dc.contributor.author | Pires, M.J. | |
| dc.contributor.author | Oliveira, P.A. | |
| dc.contributor.author | Alves, Sandra | |
| dc.date.accessioned | 2024-02-27T16:41:52Z | |
| dc.date.available | 2024-02-27T16:41:52Z | |
| dc.date.issued | 2023-02 | |
| dc.description.abstract | Mucolipidosis type II (ML II) is a Lysosomal Storage Disorder caused by the deficiency of the enzyme GlcNAc-1-phosphotransferase. This enzyme is responsible for the addition of the mannose-6-phosphate marker to lysosomal enzymes allowing their targeting to lysosomes. From the several ML II mutations, the deletion of two nucleotides from GNPTAB exon 19 (c.3503_3504del) is the most frequent, making it a good target for a mutation specific therapy. In this study, we explored an innovative therapeutic strategy based on the use of antisense oligonucleotides (ASOs) for ML II. In a previous study1 on fibroblasts from ML II patients, ASOs were used to skip exon 19 of the GNPTAB pre-mRNA, successfully resulting in the production of an in-frame mRNA. Currently, our objective is to evaluate the therapeutic potential of this approach, both in vitro in C57BL/6 fibroblasts and in vivo in C57BL/6 mice. | pt_PT |
| dc.description.version | N/A | pt_PT |
| dc.identifier.uri | http://hdl.handle.net/10400.18/9146 | |
| dc.language.iso | eng | pt_PT |
| dc.subject | Mucolipidosis Type II | pt_PT |
| dc.subject | Lysosomal Storage Disorder | pt_PT |
| dc.subject | Genética Humana | pt_PT |
| dc.subject | Doenças Genéticas | pt_PT |
| dc.title | An Antisense Oligonucletide based therapy for a rare disease: in vitro and in vivo studies | pt_PT |
| dc.type | conference object | |
| dspace.entity.type | Publication | |
| oaire.citation.conferencePlace | Bilbao, Espanha | pt_PT |
| oaire.citation.title | Delivery of Antisense RNA Therapeutics (DARTER) Final meeting of the Cost Action CA17103, 22-24 February 2023 | pt_PT |
| rcaap.rights | restrictedAccess | pt_PT |
| rcaap.type | conferenceObject | pt_PT |
